

EMERGENCY MEDICAL SERVICES AUTHORITY

10901 GOLD CENTER DR., SUITE 400
RANCHO CORDOVA, CA 95670
(916) 322-4336 FAX (916) 324-2875



DATE: November 12, 2021
TO: Local EMS Agency Administrators and Medical Directors
FROM: Dave Duncan MD
Director, EMS Authority
**Subject: Expanded Scope of Practice – Paramedic Monoclonal Antibody Infusion/
Monitoring**

This memo expands the current paramedic scope of practice at static sites, to include the administration and/or monitoring of Monoclonal Antibody (mAb) infusions when overseen by a nurse and/or physician and after receiving mAb infusion education, training and administration protocols to treat and prevent Coronavirus (COVID) in California pursuant to Governor's Office Executive Order [N-21-21](#); which states:

1. *The timeframes set forth in EO [N-12-21](#), paragraphs 1 through 6, are hereby extended through March 31, 2022.*

The EO [N-12-21](#) issued by Governor Newsom on August 16, 2021 states:

- 4) *Paragraph 40(c) of Executive Order N-08-21 is hereby withdrawn and replaced with the following text: Paragraph 4 of Executive Order N-25-20 shall remain in place and shall have full force and effect through December 31, 2021, after which time this provision shall be deemed expired.*

The EO [N-25-20](#) issued by Governor Newsom on March 12, 2020 states

4. *Notwithstanding Health and Safety Code section 1797.172(b), during the course of this emergency, the Director of the Emergency Medical Services Authority shall have the authority to implement additions to local optional scopes of practice without first consulting with a committee of local EMS medical directors named by the EMS Medical Directors Association of California.*

Paramedics are authorized to conduct mAb administrations, and/or monitoring, only when overseen by a Nurse and/or Physician. The Paramedic shall receive training and education in therapies, and administration protocols, etc.

Local EMS agencies who choose to utilize this expanded scope will not be required to submit a Local Optional Scope of Practice application. The termination date of this expanded scope is **March 31, 2022**.

For information on mAb therapies, medications their side effects, and training information visit:

- [Centers for Disease Control](#)
- [Centers for Medicare & Medicaid Services](#)
- [National Institutes of Health](#)

If you have additional questions, please contact ScopeofPractice@emsa.ca.gov.